Vaccine effectiveness of two doses against covid-19 related hospital admission at the time of delta variant circulation in France between 1 July and 20 August 2021
| Vaccine product and vaccination status | No of individuals in hospital/Total No in group (%) | Median (IQR) follow-up (days) | Model 1 (HR, 95% CI)* | Model 2 (adjusted HR, 95% CI)† | Vaccine effectiveness (%, 95% CI) |
| BNT162b2—No | 1658/1 984 730 (0.08) | 87 (63 to 109) | 1 | 1 | — |
| BNT162b2—Yes | 202/1 984 730 (0.01) | 87 (63 to 109) | 0.12 (0.11 to 0.14) | 0.11 (0.10 to 0.13) | 89 (87 to 90) |
| mRNA-1273—No | 175/239 651 (0.07%) | 89 (64 to 107) | 1 | 1 | — |
| mRNA-1273—Yes | 9/239 651 (0%) | 89 (64 to 107) | 0.05 (0.03 to 0.10) | 0.05 (0.02 to 0.10) | 95 (90 to 98) |
| ChAdOx1-S—No | 430/763 455 (0.06%) | 43 (28 to 58) | 1 | 1 | — |
| ChAdOx1-S—Yes | 44/763 455 (0.01%) | 43 (28 to 58) | 0.10 (0.07 to 0.14) | 0.09 (0.06 to 0.12) | 91 (88 to 94) |
IQR=interquartile range; HR=hazard ratio; CI=confidence interval; Yes=vaccinated; No=unvaccinated.
*Model 1: adjusted for matching variables (age, sex, region of residence, nursing home status).
†Model 2: model 1 with further adjustment for social deprivation index, history of positive covid-19 status, history of influenza vaccination, frailty, alcohol related conditions, smoking related conditions, hypertension, diabetes mellitus, dyslipidaemia, obesity related conditions, coronary heart disease, heart failure, cardiac rhythm disorder, valvular heart disease, occlusive peripheral arterial disease, stroke, pulmonary embolism, chronic respiratory conditions, dialysis, having a transplanted kidney, liver failure, active cancer, depression, psychosis, dementia, epilepsy, Parkinson’s disease, inflammatory bowel disease, rheumatoid arthritis, and ankylosing spondylitis.